Core Viewpoint - Ocugen, Inc. is set to host a conference call and live webcast on November 8, 2024, to discuss its third quarter 2024 financial results and provide a business update [1][2]. Company Overview - Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines aimed at improving health and offering hope to patients globally [3]. - The company is advancing a breakthrough modifier gene therapy platform that has the potential to treat multiple retinal diseases with a single product, alongside research in infectious and orthopedic diseases to address unmet medical needs [3]. Conference Call Details - The pre-market earnings announcement will coincide with the conference call on November 8, 2024 [2]. - Dial-in numbers for the call are (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers, with a Conference ID of 9923172 [2]. - A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site [2].

Core Viewpoint - Ocugen, Inc. has announced the lifting of the clinical hold by the FDA on its investigational new drug application for OCU200, a treatment for diabetic macular edema (DME) [1] Company Overview - Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines [5] - The company aims to improve health and offer hope for patients globally through innovative scientific approaches [5] Clinical Trial Details - The Phase 1 clinical trial for OCU200 is designed to treat patients with DME, targeting the underlying disease mechanisms through the integrin pathway [2][3] - The trial will be a multicenter, open-label, dose-ranging study with three cohorts assessing the safety of OCU200, and a fourth cohort combining OCU200 with anti-VEGF therapy [3] Disease Context - DME is a common vision-threatening disease affecting approximately 746,000 people in the United States, characterized by blurriness and progressive vision loss [4] - The prevalence of DME is increasing due to the rising number of diabetes cases in the U.S., making it crucial to address this condition [3] Future Indications - Ocugen intends to explore additional indications for OCU200, potentially treating diabetic retinopathy and wet age-related macular degeneration, which together affect nearly nine million Americans [4]

Core Insights - Ocugen, Inc. is set to present at the 2024 Cell & Gene Meeting on the Mesa, highlighting its focus on gene and cell therapies, as well as vaccines [1][2] - Dr. Shankar Musunuri will discuss Ocugen's modifier gene therapy platform and ongoing clinical trials for retinal diseases, including OCU400, OCU410, and OCU410ST [2][4] - The company aims for BLA and MAA approval for OCU400 by 2026, with the Phase 3 trial currently in progress [2] Company Overview - Ocugen, Inc. is a biotechnology firm dedicated to developing innovative gene and cell therapies and vaccines to improve global health [4] - The company emphasizes its commitment to addressing unmet medical needs in retinal diseases and infectious diseases [4] Event Details - The presentation by Dr. Musunuri is scheduled for October 7, 2024, at 1:30 p.m. MST at the Arizona Biltmore [3] - Virtual attendance options are available for the presentation and other conference sessions [3]

MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development, will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, at Chardan's 8th Annual Genetic Medicines Conference being held Septembe ...

Jonathan Storey Source: Corporate Presentation. August 2024. Ocugen Inc. (NASDAQ:OCGN) is a clinical-stage biotechnology company developing gene and cell therapies using its proprietary platforms. They aim to restore retinal function in various ocular diseases. Since I last covered OCGN, the company has made promising strides targeting conditions such as retinitis pigmentosa [RP], goographic atrophy related to dry age-related macular degeneration [dAMD], Stargardt disease, and wet AMD. It also has an intrig ...

Core Insights - Ocugen, Inc. is participating in a workshop titled "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks" from September 9-11, 2024, in New Delhi, India, with Dr. Shankar Musunuri representing the company [1][2] - The workshop aims to explore opportunities for U.S.-India biotechnology collaboration, aligning with the initiative on Critical and Emerging Technology (iCET) [2] - Ocugen has established a site in Hyderabad, India, to enhance collaboration in the biotechnology sector [2] Company Overview - Ocugen, Inc. focuses on discovering, developing, and commercializing novel gene and cell therapies, and vaccines aimed at improving global health [3] - The company is advancing a breakthrough modifier gene therapy platform that has the potential to treat multiple retinal diseases with a single product [3] - Ocugen is also conducting research in infectious diseases and orthopedic diseases to address unmet medical needs [3]

Core Insights - Ocugen, Inc. is participating in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York, NY, where Dr. Shankar Musunuri will engage in a fireside chat [1][2] - The conference serves as a platform for Ocugen to showcase its recent corporate achievements and future milestones, with one-on-one meetings planned for investors [2] Event Details - The fireside chat is scheduled for September 9, 2024, at 1:30 p.m. ET, located at the Lotte New York Palace Hotel [3] - A live video webcast of the presentation will be available on Ocugen's investor site, with a replay archived for 90 days [3] Company Overview - Ocugen, Inc. focuses on discovering, developing, and commercializing novel gene and cell therapies, and vaccines aimed at improving global health [4] - The company is advancing a unique modifier gene therapy platform that has the potential to treat multiple retinal diseases with a single product, alongside research in infectious and orthopedic diseases [4]

MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease affects approximately 100,000 people in the United States (U.S.) an ...

Ocugen, Inc. (OCGN) announced that Health Canada has provided it a No Objection Letter to initiate the phase III liMeliGhT study evaluating its modifier gene therapy product candidate, OCU400, for treating retinitis pigmentosa (RP). Shares of OCGN were up 4.6% on Aug. 26 following the announcement of the news. Ocugen has already received clearance from the FDA to initiate a phase III study on OCU400 for the treatment of RP, a rare genetic disorder that can lead to vision loss and blindness. The FDA had prev ...

MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a "No Objection Letter" to initiate the OCU400 Phase 3 liMeliGhT (pronounced "limelight") clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). "Expanding the clinical ...